Virologic Response Associated With a Change in Protease Inhibitor Therapy

In the report by Guardiola and colleagues,¹ a switch in protease inhibitor (PI) therapy for reasons other than therapeutic failure occurred in 74% of patients who were treated with PI-based regimens. The therapeutic strategy in these patients needs careful assessment before PI changes, since the patients may be put at greater risk for therapeutic failure after therapy change.